WHO asks Serum Institute of India for Covishield trial data to begin global supply

Serum Institute of India is one of the manufacturers that has signed up to supply up to 400 million doses of vaccines to the Covax Facility. In the first quarter, the company is expected to supply 200 million doses of the AstraZeneca/Oxford vaccine which it has developed in India and branded as Covishield.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news